Published Date: 24 Apr 2023
Germany: One mechanism underlying the rise in has been revealed by a research team at the University of Cologne's CECAD Cluster of Excellence in Aging Research.
Read Full NewsAn AES study revealed the real-world persistence of fenfluramine in treating Lennox-Gastaut syndrome, highlighting patient demographics and treatment trends.
Final safety data from an open-label study presented at AES 2025 supported long-term fenfluramine use in pediatric and adult patients with Dravet syndrome or Lennox-Gastaut syndrome.
Low-Intensity Ultrasound Brain Stimulation Safely Reduces Depression Symptoms
Exercise May Be as Effective as Therapy for Alleviating Depression Symptoms
Parental Illness Perceptions Drive Poor QoL in Children with Food Allergies
Young Adults With Glomerular Disease May Require Distinct Care
Q4 2025 Recap: Nephrology News and Updates
1.
Even when they are not paying attention, children are still learning.
2.
Survivors of high-risk neuroblastoma face substantial late effects of modern therapies
3.
Kate Middleton Reaches Cancer Treatment Milestone
4.
Pulled Myeloma Drug Improves Survival in Trial
5.
Genetics and Genetic Testing to Inform Myelofibrosis Clinical Management.
1.
Breast Cancer Secrets: AI-Powered Precision Medicine
2.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
3.
Surprising Symptoms of Prostate Cancer: What You Need to Know
4.
Empowering Lung Cancer Diagnosis Through the Synergy of Advanced Technologies and Artificial Intelligence
5.
Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation